PF Warriors - Pulmonary Fibrosis, IPF, other Rare Lung Diseases

05/29/2025

Since his diagnosis of pulmonary fibrosis (PF) caused by rheumatoid arthritis in 2015, PF Warrior Jim McDonald has made it a priority to travel more and spend time in the places that bring him peace, especially hiking in National and State Parks.

This year has been a busy one, but he finally made it to Valley of the Fire State Park! Jim said he's always wanted to visit, and it's just a couple hours outside of Las Vegas. He said being there gave him a deep sense of connection and reminded him why it's so important to make time for what matters most.

He lives by two quotes that guide his approach to life with PF:

“If you rest, you rust.” Unknown
“They’re all good days. Some are just better than others.” His Dad

It’s moments like these that remind us how meaningful it is to stay connected to what we love. We hope his experience speaks to your ❤️💙 like it did for ours!

Want to be featured on the PF Warriors page? Share a favorite photo of you living your best possible life after diagnosis below!

05/28/2025

Before the conference, we invited PF Warriors to share messages they wished doctors, nurses, researchers, and clinicians could hear, the heartfelt expressions of what it means to live with pulmonary fibrosis.

They responded with honesty and hope:

❤️ Faith
💙 I have a life to live
❤️ Breathless, not voiceless

At our booth, we asked professionals to write messages in return. Notes of empathy, encouragement, and shared commitment. Their words moved us:

💙 You are heard and seen
❤️ Hoping to develop new treatments to help
💙 We are with you—keep fighting
❤️ Empathy and understanding

We're all in this together!

05/26/2025

This Memorial Day, we pause to remember the heroes who gave everything in service to our country. Their courage, sacrifice, and devotion to duty are not forgotten.

05/24/2025

"Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B), in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), respectively, with and without background antifibrotic therapy. Results were published in the New England Journal of Medicine and also presented as a late-breaking abstract at the American Thoracic Society (ATS) 2025 International Conference.

Nerandomilast is an investigational agent and has not been approved for use; its efficacy and safety has not been established." - To read the press release in full please visit: https://www.boehringer-ingelheim.com/us/fibroneer-data-presented-ats-and-published-nejm

05/23/2025

Read how PF Warriors represented YOU while at the American Thoracic Society conference this week!

"Throughout the week, PF Warriors leaders, volunteer staff, and patient members took part as speakers and panelists in a number of key sessions. Volunteer team members and patients, themselves, Theresa Genovese and Maryluz Fuentes, MD, along with patient Yvonne Chamberlain, shared their perspectives in ATS scientific sessions."

MaryLuz Fuentes, MD, speaks to American Thoracic Society conference attendees Theresa Genovese at the American Thoracic Society meeting Yvonne Chamberlain, Patient Speaker at the American Thoracic Society meeting Leadership, volunteers, patients engages with global experts at American Thoracic Socie...

05/19/2025

PF Warriors is proud to be at the American Thoracic Society for this year's ! ❤️💙

Here's a peek at our booth #1931, where we're sharing the work of PF Warriors with researchers, clinicians, doctors, nurses, and pharmaceutical attendees!

Can you name some or all of the people who are shown at our booth? Let us know in the comments below!

05/19/2025

“We’re encouraged by the positive results from the FIBRONEER-IPF trial and the possibility of another FDA-approved therapy option for people living with pulmonary fibrosis.”

- Dolly Kervitsky, RCP, CCRC, CNP
President, PF Warriors

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa...

05/16/2025

Join us for our monthly PF Warriors open question and answer meeting that's led by patients and caregivers. Ask questions and learn more about living with pulmonary fibrosis (PF).

🗓️ May 22nd
⏰ 10am CT
🔗 https://bit.ly/W2WMAY2025

We, as patients and caregivers, are here to support and help each other. Whether you have questions or can contribute answers, your presence is valuable.

Register Now! https://bit.ly/W2WMAY2025

Have questions? Email us ahead of the meeting: Meetings@PFWarrior.com.

Upon registering, you will receive a confirmation email
with details on how to join the meeting.

05/15/2025

Over the weekend, our PF Warrior Natalie graduated with her Associate of Science degree from Northwest Technical College through their LPN Step-In Program, which helps licensed practical nurses become registered nurses. Very appropriately timed during National Nurses Week!

Natalie recently shared, “Thank you Warriors for (unknowingly) helping me through the past 15 months of school. Your daily posts and comments are always a source of comfort and a go-to for me when I’m not feeling well or feeling overwhelmed.”

We are so proud of you, Natalie! And we ❤️💙 knowing that our motto of Patients Helping Patients played a role in helping you accomplish this goal!

Please join us in congratulating Natalie on her incredible achievement!

05/13/2025

🌍 Oxygen is life—and long-term oxygen therapy (LTOT) is too often overlooked.

A recent Lancet Global Health commentary highlights a major gap: LTOT access for people with conditions like pulmonary fibrosis, ILD, and post-TB lung disease, especially in low-resource settings.

✅ LTOT improves survival and quality of life
⚠️ But global plans often focus only on short-term hospital use
💡 We need data, access, infrastructure, and innovation—especially for home oxygen

LTOT isn’t optional—it’s essential.
Let’s make sure no one is left struggling to breathe.

Learn more: https://www.thelancet.com/action/showPdf?pii=S2214-109X%2825%2900120-2

05/09/2025

This Nurses Week, we thank the extraordinary nurses who walk beside our PF Warriors every step of the way.

Your skill and presence bring comfort on the hardest days and hope when it's needed most. We appreciate and honor you, not just this week, but always.

05/08/2025

PF Warriors is proud to attend and exhibit at the annual American Thoracic Society (ATS) International Conference, one of the largest educational meetings for healthcare professionals focused on pulmonary, critical care, and sleep medicine in San Francisco, CA, May 16 - 21.

PF Warriors will be at Booth 1931, representing the patient voice, advocating for the community, and helping expand awareness of pulmonary fibrosis (PF) and interstitial lung disease (ILD).